Pfizer's Dividend Yield is 10X Bigger Than Eli Lilly's. Does That Make It the Better Stock for Income Investors?

Eli Lilly is thriving in the GLP-1 weight-loss drug market with strong sales growth, but offers minimal dividend yield of 0.6%. Pfizer, struggling with patent expirations and GLP-1 setbacks, offers a much higher 6.6% dividend yield. While Pfizer faces near-term headwinds, income-focused investors willing to accept risk may find value in its substantial dividend, though the payout ratio exceeding 100% raises concerns.